



Updated Monthly

February 5, 2024

Prepared for:



THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:




Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com

  @G2Gconsulting





GBG Report

Updated Monthly

February 5, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

TABLE OF CONTENTS

New Opportunities

| | |
|--|----|
| Advanced Research Projects Agency for Health | 2 |
| Aging..... | 3 |
| Agriculture..... | 3 |
| Autism..... | 4 |
| Biotechnology and Biomanufacturing..... | 4 |
| Cancer | 5 |
| Central Nervous System | 5 |
| Chronic Pain & Pain Management | 6 |
| Climate Science | 6 |
| Cognitive and Brain Health..... | 6 |
| Combat Casualty Care..... | 7 |
| Complementary and Integrative Health..... | 7 |
| Coronavirus | 8 |
| Down Syndrome | 8 |
| Endocrine & Metabolic Disease | 8 |
| Genomics | 9 |
| Health IT & Data..... | 9 |
| Hearing Restoration..... | 10 |
| HIV/AIDS | 10 |

| | |
|---------------------------------------|----|
| Immunology & Infectious Disease | 10 |
| Joint Warfighter Medical..... | 11 |
| Patient-Centered Research | 12 |
| Radiation Exposure..... | 12 |
| Substance Use Disorder | 13 |
| Therapeutics..... | 13 |
| Tuberous Sclerosis Complex | 14 |
| Vision Health | 14 |

Recurring Opportunities

| | |
|--|----|
| Advanced Research Projects Agency for Health | 15 |
| Air Force | 15 |
| Army..... | 16 |
| BARDA | 17 |
| DARPA | 18 |
| Defense Threat Reduction Agency | 18 |
| Department of Energy..... | 18 |
| National Science Foundation | 19 |
| Navy | 19 |

| | |
|---------------------------|-----------|
| GBG Acronyms | 20 |
|---------------------------|-----------|



February 15, 2024 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm EST (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Health Industry Forum, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, or VaBio – your membership gets you access to the private consultation webinar.

MHSRS News: The [MHSRS abstract submission window](#) is now open! Abstracts are due by February 21, with the conference to be held in August. On **February 14**, G2G is [hosting a webinar with tips on submitting to MHSRS](#) and will also share information about OpMed in March, and the SOMA conference in May.

| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|----|---|--|---|---|
| | | ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4) | | |
| 1. | Draft: HHealth care Rewards to Achieve Improved OutcomES (HEROES) (ARPA-H) ARPA-H-SN-24-04 | Under the HEROES program, public health entities and collaborators will have the opportunity to improve the health status of their communities for specific patient populations as the program evaluates a new payment model that incentivizes community-based interventions to improve health outcomes across a fixed geography. These solutions will investigate a new regionally focused outcomes-based financing approach for the healthcare industry, which rewards only positive health outcomes and reduces the health care burden on patients, providers, and the economy. Health Outcomes of Interest are: Maternal Health; Heart Attack and Stroke Risk; Opioid Overdose' Alcohol-Related Health Harms. https://sam.gov/opp/75396c6908354c25a832e589d0ad4aab/view | \$99 million in total funding | Proposer's Day: 2/13-14/24 Draft closes: 2/20/24 Estimated post date: 4/4/24 Estimated abstract due date: 5/31/24 Estimated proposal due date: 10/31/24 |
| 2. | Draft: Transplantation of Human Eye Allografts (THEA) (ARPA-H) ARPA-H-SN-24-07 | The THEA program aims to make whole eye transplantation a reality for the recovery of vision loss in patients with total blindness from retinal and optic nerve disease. We believe the great advancements over the last two decades in technology, transplantation surgery, and regenerative medicine now make restoration of vision from whole eye transplantation possible. https://sam.gov/opp/e706db0eaca64e0cae0c8073ef9e20a0/view | Dependent upon proposal and available funding | Proposer's Day: 2/15/24 Abstract: 3/1/24 Proposal: 4/15/24 |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|----|---|--|---|----------------------|
| | | ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH | | |
| 3. | Platform Accelerating Rural Access to Distributed & InteGrated Medical care (PARADIGM) (ARPA-H) ARPA-H-SN-24-06 | PARADIGM will deliver hospital-level care via a multi-purpose Care Delivery Platform (CDP) that is as convenient as telehealth. The CDP will pioneer new developments in point-of-care diagnostics, ensure seamless data exchange between medical devices and electronic health records (EHRs), and offer real-time guidance for medical tasks. https://sam.gov/opp/3f79c4f4217e4ef8880c712ce27f622a/view | Dependent upon proposal and available funding | Abstract: 2/26/24 |
| 4. | Research and development (R&D) that will contribute toward ARPA-H mission needs and SBIR program objectives. (ARPA-H) 75N91024R00006 | ARPA-H invites proposals that possess the R&D expertise to conduct innovative research in the following research topics: ARPA-H 01 - Inexpensive plant-based manufacturing of viruses; ARPA-H 02 - LymphoLab ProDiscover Kit; ARPA-H 03 - Continuous Monitoring of Vascular health using Smart Biomimetic Implantables; ARPA-H 04 - Personalized medicine platform for predicting response to immunotherapy; ARPA-H 05 - Saving Baby Hearts: Fully Autonomous Neonatal Echocardiography for the Diagnosis of Critical Congenital Heart Disease; ARPA-H 06 - Improving Identity and Access Management with Clinical Context. https://sam.gov/opp/a738f57f6f884dd49f3135c97b037d95/view | Up to \$600,000, for up to 2 years (Phase I) Up to \$3.5 million, for up to 3 years (Phase II) | Proposal: 2/22/24 |
| | | AGING (1) | | |
| 5. | 2024 US NAM Catalyst Award Competition (NAM) | The NAM is currently seeking bold, new, and innovative ideas that aim to extend the human healthspan, especially approaches that challenge existing paradigms or propose new methodologies or concepts. High-risk ideas that could potentially yield high rewards and, in turn, dramatically change the field of healthy longevity are encouraged. https://nam.edu/initiatives/grand-challenge-healthy-longevity/u-s-nam-catalyst-award-competition-round-2-2021/ | \$50,000 | Proposal: 3/11/24 |
| | | AGRICULTURE (1) | | |
| 6. | Agricultural Genome to Phenome Initiative (USDA/NIFA) USDA-NIFA-OP-010573 | The AG2PI focuses on collaborative science engagement that intends to develop a community of researchers across both crops and animals that will lay the foundation for expanding knowledge concerning genomes and phenomes of importance to the agriculture sector of the United States. The goals require interdisciplinary approaches that combine technologies such as advanced computing, automated high throughput phenotyping and genotyping as well as climatic modelling to be successful. https://www.nifa.usda.gov/grants/funding-opportunities/agricultural-genome-phenome-initiative | Up to \$1.2 million Cost sharing required | Proposal: 5/30/24 |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|--|---|---|---|
| | | AUTISM (1) | | |
| 7. | Forecast: FY24 Autism Research Program (ARP) (DoD/CDMRP) | The ARP supports research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (ASD). Four awards are anticipated as part of the FY24 ARP: Clinical Trial Award, Idea Development Award, Career Development Award, and Discovery Award. https://cdmrp.health.mil/pubs/press/2024/24arppreann | Up to \$2.2 million, for up to 4 years Dependent upon award mechanism | TBD |
| | | BIOTECHNOLOGY AND BIOMANUFACTURING (3) | | |
| 8. | Future Manufacturing (FM) (NSF) NSF 24-525 | The goal of Future Manufacturing is to support fundamental research, education, and training of a future workforce to overcome scientific, technological, educational, economic, and social barriers in order to catalyze new manufacturing capabilities that do not exist today. Three thrust areas have been identified for support: Future Cyber Manufacturing, Future Eco Manufacturing, and Future Biomanufacturing research. https://www.nsf.gov/pubs/2024/nsf24525/nsf24525.htm | Up to \$3 million, for up to 4 years Dependent upon award mechanism | Proposal: 4/11/24 |
| 9. | Biological Technologies Office: Seedling Week (DoD/DARPA) HR001124S0020 | The purpose of DARPA Seedling Week is to rapidly award seedling efforts by streamlining the acquisition process and making “on the spot” awards the same day as Oral Presentations to DARPA. Prior to the Oral Presentations, proposers will be required to submit a Proposal Submission and Presentation (PSP) package one week in advance. This rapid award model will allow DARPA to explore and fund promising new ideas that could possibly inform new “programs” and technology spaces in a historically short time frame. Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. https://sam.gov/opp/2ee7fbc0fba2423e860a4076777dad6b/view | Up to \$500,000 | Abstract: 2/14/24 Invited proposal: 3/18/24 Oral presentation: week of 3/25/24 |
| 10. | Distributed Bioindustrial Manufacturing Investment (DoD/DIBC) | The DoD seeks to engage in prototype projects in the 5Fs that will develop and demonstrate technical and business processes to produce pure, stable, high-quality biomanufactured product(s). “5Fs”: Food, Fuel, Fitness, Fabrication, Firepower. Materials of interest shall address current and evolving DoD needs, such as resolving long-term shortages, filling a gap in the domestic industrial base, or bioproduction of material that cannot be, or is no longer able to be, produced through conventional processes. Bioproduction of materials with improved performance characteristics is also of interest. https://www.dibconsortium.org/event/distributed-bioindustrial-manufacturing-request-for-white-paper-released/ | Dependent upon proposal and award mechanism Successful applicants must be consortium members at the time of award. | Enhanced white paper: 3/6/24 |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|--|--|---|---|
| | | CANCER (7) | | |
| 11. | Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) (NIH/NCI) PAR-24-122 | The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science. https://grants.nih.gov/grants/guide/pa-files/PAR-24-122.html | Up to \$250,000 per year, for up to 5 years | Proposal: 6/5/24 |
| 12. | Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional (FDA/OC/OCE) RFA-FD-24-038 | This NOFO will fund research to develop approaches to support drug development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. The NOFO focuses on supporting studies to improve therapeutic development in ultra-rare cancers with high unmet medical need where there is little economic incentive for commercial entities to conduct the research. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-038.html | Up to \$500,000 per year, for up to 3 years | Letter of intent: 2/19/24 Proposal: 4/5/24 |
| 13. | Forecast: FY24 Lung Cancer Research Program (DoD/CDMRP) | The FY24 LCRP anticipates 5 awards: Concept Award, Career Development Award, Idea Development Award, Translational Research Award, Patient-Centered Outcomes and Survivorship Award. All applications must address one or more Areas of Emphasis . https://cdmrp.health.mil/pubs/press/2024/24lcrppreann | Up to \$1.2 million, for up to 4 years Dependent upon award mechanism | TBD |
| | | CENTRAL NERVOUS SYSTEM (4) | | |
| 14. | Analytical and Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01/U44 Clinical Trial Optional) (NIH/NINDS) PAR-24-095 (U01) PAR-24-096 (U44) PAR-24-097 (U01) PAR-24-098 (U44) | These NOFOs support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice; and enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. https://grants.nih.gov/grants/guide/pa-files/PAR-24-095.html (U01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-096.html (U44) https://grants.nih.gov/grants/guide/pa-files/PAR-24-097.html (U01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-098.html (U44) | Dependent upon proposal, for up to 5 years (U01) Up to \$700,000 per year, for up to 2 years (Phase I) Up to \$1.5 million per year, for up to 3 years (Phase II) (U44) | Multiple deadlines; NOFOs open through 6/23/26 |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|--|---|---|--|
| | | CHRONIC PAIN & PAIN MANAGEMENT (1) | | |
| 15. | Forecast: HEAL KIDS (Knowledge, Innovation and Discovery Studies): Chronic Pain Program (UC2 Clinical Trial Optional) (NIH) NOT-AR-24-006 | This NOFO will solicit applications for multi-PI team-based, challenging, high impact projects to improve understanding of mechanisms of chronic pain in children and adolescents and to accelerate the development of age appropriate, patient/family centered prevention and therapeutic approaches. This research will seek to advance an integrated understanding of the biological, psychological, and social factors that contribute to pediatric chronic pain. NIH is interested in pain research in infants, children, and adolescents that includes those with intellectual and physical disabilities and/or those who experience health disparities. https://grants.nih.gov/grants/guide/notice-files/NOT-AR-24-006.html | TBD | Estimated post date: 5/10/24 Estimated proposal date: 11/10/24 |
| | | CLIMATE SCIENCE (1) | | |
| 16. | Center of Excellence in Climate Measurements (CECM) Program (DoC/NIST) 2024-NIST-CECM-01 | The Center will develop a suite of standardized data sets, guides, frameworks, best practices for methods, metrics, methodologies, and tools for modelling and forecasting climate trends and risks to the communities, associated with those trends. Examples of major activities include, but are not limited to: aggregating dissimilar datasets, creating and compiling new data, developing assessments and models, working with stakeholders to standardize information on the hazards and risks associated with climate trends. https://www.grants.gov/search-results-detail/352103 | Up to \$2,667,900, for up to 3 years | Proposal: 4/1/24 |
| | | COGNITIVE AND BRAIN HEALTH (4) | | |
| 17. | Forecast: NeuroNEXT Clinical Trials: Stage 1 (Preliminary) and Stage 2 (Protocol) Applications (OT2) (NIH/NINDS) NOT-NS-24-045 | This clinical research network develops and conducts scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies emerging from a range of contexts including academic, foundation or industry discoveries. The network is designed to increase the efficiency of clinical trials, facilitate patient recruitment and retention, increase the quality of neuroscience clinical trials, and enable public-private partnerships. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-045.html | TBD | Estimated post date: April 2024 Estimated proposal date: June 2024 |
| 18. | Blueprint Medtech Incubator Hub Cycle 4 Funding Solicitation (NIH/CINTA/NTH) | This program will catalyze the translation of novel technologies from early-stage development to a prototype ready for first-in-human testing and will provide: (a) non-dilutive funds to support medical device development activities, (b) ongoing, specialized support from experienced executive mentors and (c) additional resources and support services. https://blueprintneurotech.org/ | Up to \$500,000 per year, for up to 4 years Dependent upon award mechanism | Pre-proposal: 2/29/24 Invited proposal: 4/19/24 |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|---|---|---|--|
| | | COGNITIVE AND BRAIN HEALTH | | |
| 19. | Forecast: Deriving Common Data Elements from Real-World Data for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U24 Clinical Trial Not Allowed) (NIH/NIA) NOT-AG-23-080 | This NOFO will solicit applications that aim to develop Common Data Elements (CDEs) for AD/ADRD using Real-World Data (RWD) from electronic health records and Centers for Medicare & Medicaid Services (CMS) claims. The CDEs will foster data harmonization and interoperability among data systems that involve disparate and unaligned RWD. By reducing the efforts required for data harmonization in using RWD for cross-sectional and longitudinal analysis, the NOFO may enable researchers to utilize RWD more efficiently and produce real-world evidence in a faster manner. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-23-080.html | Up to \$2.5 million (FY25) Up to \$3.5 million per year (FY26-30) | Estimated post date: 3/29/24 Estimated proposal date: 6/14/24 |
| | | COMBAT CASUALTY CARE (1) | | |
| 20. | Forecast: Simulation Ecosystem Development for Validation of Emerging Technologies within the Autonomous Casualty Care (AC2) Research Portfolio (MTEC) MTEC-24-06-SimulationEcosystem | The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for a Request for Project Proposals (RPP) focused on establishing an array of venues where medics, other caregivers and simulated patients agree to participate in tactical combat casualty care (TCCC) training while wearing suites of sensing technologies. This effort is aimed at providing a controlled venue to conduct these training events that is hyper realistic with respect to battlefield conditions. https://mtec-sc.org/wp-content/uploads/2024/02/MTEC-24-06-SimulationEcosystem-PreAnnouncement_Final.pdf | Up to \$442,000 | TBD |
| | | COMPLEMENTARY AND INTEGRATIVE HEALTH (5) | | |
| 21. | NCCIH Natural Product Clinical Trials, Clinical Coordinating Center, and Data Coordinating Center (R01/R33/UG3/UH3/R61/R33/U24 Clinical Trial Required) (NIH/NCCIH) PAR-24-115 (R01) PAR-24-116 (R33) PAR-24-123 (UG3/UH3) PAR-24-124 (R61/R33) PAR-24-125 (U24) | These NOFOs will encourage applications for early and mid-phase investigator-initiated clinical trials of natural products, as well as a Clinical Coordinating Center and Data Coordinating Center. DCC and CCC applications must be submitted simultaneously. https://grants.nih.gov/grants/guide/pa-files/PAR-24-115.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-116.html (R33) https://grants.nih.gov/grants/guide/pa-files/PAR-24-123.html (UG3/UH3) https://grants.nih.gov/grants/guide/pa-files/PAR-24-124.html (R61/R33) https://grants.nih.gov/grants/guide/pa-files/PAR-24-125.html (U24) | Up to \$350,000 per year, for up to 3 years (R01) Up to \$1.05 million, for up to 3 years (R33) Dependent upon proposal, for up to 5 years (UG3/UH3/U24) Up to \$350,000 per year, for up to 5 years (R61/R33) | Multiple deadlines; NOFOs open through 11/13/26 |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|--|--|---|---|
| | | CORONAVIRUS (2) | | |
| 22. | Project NextGen: Innovation in Clinical Manufacturing of COVID-19 Vaccines (HHS/BARDA) RRPV-24-05-NGClinMfg | The purpose of this initiative is to partner with developers and other organizations to implement novel solutions to cGMP manufacturing hurdles and enable clinical trials for next-generation COVID-19 vaccines. The goal of these Project Awards is to advance innovative capabilities and improve the vaccine manufacturing enterprise to provide better COVID-19 solutions and bolster preparedness and response against future health security threats. https://www.rrpv.org/solicitation/24-05-ngclinmfg/ | Total funds of \$160 million | Proposal: 3/15/24 |
| 23. | Enabling Technology – Decentralized Clinical Trial – Retail/Pharmacy Focus (HHS/BARDA) RPP-24-02-Retail | BARDA is requesting project proposals to conduct a study designed to assess CoP using humoral immunogenicity data correlated to symptomatic COVID-19 following vaccination with an FDA licensed/authorized COVID-19 vaccine, leveraging the decentralized clinical study sites. https://www.rrpv.org/solicitation/24-02-retail/ | \$25 million total funds, for 2 years | Proposal: 3/15/24 |
| | | DOWN SYNDROME (1) | | |
| 24. | NOSI: Use of Digital Technology and mHealth to Improve Diagnosis, Assessments, Interventions, Management and Outcomes for Individuals with Down Syndrome Across the Lifespan (R21 CT Not Allowed) (NIH) NOT-OD-24-044 | There is currently a relative paucity of valid and reliable technological tools for children and adults with intellectual and developmental disabilities (IDD) with a focus on Down syndrome (DS). This NOSI invites exploratory and developmental research applications specifically aimed at developing or building upon existing technological tools to improve diagnosis, assessments, interventions, management, and outcomes for infants, children, adolescents and adults with DS. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-044.html | Up to \$275,000, for up to 2 years | Multiple deadlines; NOSI open through 2/13/25 |
| | | ENDOCRINE & METABOLIC DISEASE (2) | | |
| 25. | Forecast: Diabetes Research Centers (P30 CT Optional) (NIH/NIDDK) NOT-DK-24-009 | The DRC program is intended to bring together investigators from a variety of scientific disciplines in a manner that enhances and extends the effectiveness of their research. The DRC must have a central research focus or theme in diabetes and/or related endocrinology and metabolic diseases. https://grants.nih.gov/grants/guide/notice-files/NOT-DK-24-009.html | \$7.5 million total funding | Estimated post date: 3/1/24 Estimated proposal date: 6/18/24 |
| 26. | Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in T1D (R01 CT Required) (NIH/NIDDK) RFA-DK-23-011 | This NOFO solicits applications for studies that will develop and test risk mitigation strategies that involve the clinical integration of CKM for the safe use of SGLT2i for people living with T1D so that they may benefit from the cardiac and renal protection and glucose-lowering effects of this drug class. The NOFO will support short-term, clinical trials to gain and disseminate knowledge on safety and glucose control with CKM and SGLT2i use. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-011.html | Up to \$500,000 per year, for up to 3 years | Letter of intent: 5/27/24 Proposal: 6/27/24 |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|---|--|--|--|
| | | GENOMICS (6) | | |
| 27. | Solutions to Enable Regional Genomic Medicine eConsult Services (R43/R44/R41/R42 Clinical Trial Optional) (NIH/NHGRI) PAR-24-106 (R43/R44) PAR-24-107 (R41/R42) | A variety of solutions that can enable eConsult services are needed. NHGRI will consider applications that address barriers to setting up eConsult services; conducting outreach, promotion, and education about eConsult services; and/or providing eConsults. Eligible small businesses can submit applications focusing on solutions that reduce costs, time, and/or increase access to regional genomic medicine eConsult services. https://grants.nih.gov/grants/guide/pa-files/PA-24-106.html (R43/R44) https://grants.nih.gov/grants/guide/pa-files/PA-24-107.html (R41/42) | Up to \$400,000, for up to 2 years (Phase I) Up to \$2.15 million, for up to 3 years (Phase II) | Letter of intent: 4/30/24 Proposal: 5/30/24 |
| 28. | Research on the Impact of and Methods for Implementing Regional Genomic Medicine eConsult Services (U01 Clinical Trials Optional) (NIH/NHGRI) RFA-HG-24-001 | The eConsult Network will consist of 2-3 sites and NHGRI. Each site will conduct research to determine the impact of and methods for implementing regional clinician-to-clinician genomic medicine eConsult services. This program is intended to address three overarching research questions: What impact do genomic eConsult services have when they are implemented at the regional level? How can regional genomic eConsult services be implemented and sustained? Can tools be created and shared with others who are creating regional eConsult services? https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-24-001.html | Up to \$4.87 million, for 5 years | Letter of intent: 4/30/24 Proposal: 5/30/24 |
| 29. | NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed) (NIH/NHGRI) RFA-HG-24-013 | NHGRI seeks to fund a Coordinating Center that will expand the support and coordination of technology development efforts funded by NHGRI. The goal is to accelerate technology development and progress in the field of genomics. https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-24-013.html | Up to \$1.5 million per year, for up to 5 years | Letter of intent: 3/1/24 Proposal: 4/2/24 |
| 30. | NOSI: RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH) (NIH/NCI/NIAID/NCATS) NOT-AI-24-007 | This NOSI aims to support the development and/or pre-clinical studies of non-viral technologies to deliver RNA-based therapeutics into disease-relevant cells and tissues in vivo. Projects may focus on a single or multiple cells or tissues. Emphasis will be placed on organs, tissues and cell types that are clinically relevant but for which no effective in vivo delivery technologies are currently available. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-007.html | Dependent upon proposal and award mechanism | Multiple deadlines; NOSI open through 1/5/27 |
| | | HEALTH IT & DATA (2) | | |
| 31. | Agile Medical Countermeasure Decision Support Tool (AMDST) Prototype (MTEC) MTEC-24-04-AMDST | This RPP is focused on the development of a software prototype that will allow a medical planner to assess the residual operational risk for a mission after layering in threat risk, medical countermeasure (MCM) risk-benefit tradeoffs, and fielding risk during mission planning. The AMDST layering model is intended to include all MCMs for a potential threat, including FDA-approved, repurposed, and investigational drugs. https://mtec-sc.org/wp-content/uploads/2024/01/MTEC-24-04-AMDST-RPP-Final.pdf | Dependent upon proposal, for up to 3 years | Enhanced white paper: 2/15/24 |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|---|--|--|---|
| | | HEALTH IT & DATA | | |
| 32. | Forecast: Passive Data Collection using Autonomous Documentation (AutoDoc) Project – Development of Passive Sensor Suite (MTEC) MTEC-24-05-AutoDocSensor | MTEC anticipates posting an RPP with the objective of developing a system of sensor suites that can reliably and passively collect the core data needed to identify casualty status, key tasks performed by medics, and real-time resource use in casualty care scenarios under realistic battlefield conditions. To enhance TCCC and improve medical documentation in the MHS, a passive, autonomous documentation solution of medical care in operational environments is an essential requirement to establishing these critical TCCC data sets. https://mtec-sc.org/wp-content/uploads/2024/01/MTEC-24-05-AutoDocSensor-Pre-Announcement.pdf | Up to \$1.5 million for up to 2 years; 2 awards anticipated | TBD |
| | | HEARING RESTORATION (1) | | |
| 33. | Forecast: FY24 Hearing Restoration Research Program (DoD/CDMRP) | The FY24 HRRP anticipates granting the Focused Research Award, which has 3 different funding levels. Applications must address one or more of the Focus Areas . https://cdmrp.health.mil/pubs/press/2024/24hrrppreann | Up to \$1 million, for up to 3 years Dependent upon award mechanism | TBD |
| | | HIV/AIDS (1) | | |
| 34. | High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) (NIH/NIDA) RFA-DA-25-060 | This NOFO invites research projects with the potential to open new areas of basic and clinical HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use addictive substances. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-060.html | Up to \$1.5 million per year, for up to 5 years | Multiple deadlines; NOFO open through 2/12/27 |
| | | IMMUNOLOGY & INFECTIOUS DISEASE (5) | | |
| 35. | Understanding Mechanisms and Outcomes of Trained Immunity (R21/R01 Clinical Trial Not Allowed) (NIH/NIAID) PAR-24-111 (R21) PAR-24-112 (R01) | These NOFOs support research that improves understanding of basic mechanisms and biomarkers of trained immunity, plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation. https://grants.nih.gov/grants/guide/pa-files/PAR-24-111.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-24-112.html (R01) | Up to \$275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01) | Multiple deadlines; NOFOs open through 1/7/27 |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|--|--|---|--|
| | | IMMUNOLOGY & INFECTIOUS DISEASE | | |
| 36. | NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44/U01 Clinical Trial Required) (NIH/NIAID) PAR-24-099 (U44) PAR-24-100 (U01) | These NOFOs encourage cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High-risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and may be proposed under this program. https://grants.nih.gov/grants/guide/pa-files/PAR-24-099.html (U44) https://grants.nih.gov/grants/guide/pa-files/PAR-24-100.html (U01) | Up to \$300,000 per year, for up to 2 years (Phase I) Up to \$1 million per year, for up to 3 years (Phase II) Waiver topics may exceed these amounts (U44) Dependent upon proposal, for up to 5 years (U01) | Multiple deadlines; NOFOs open through 1/13/27 |
| 37. | Vaccine (and other Biologic) Manufacturing Services for Infectious Diseases (NIH/NIAID) 75N93024R00004 | To support the development and introduction of new vaccines and biologics against potential agents of bioterrorism, drug-resistant pathogens, emerging and re-emerging infectious diseases, as well as infectious diseases prevalent in resource-limited countries that remain a high public health priority. To assist in filling these public health gaps, NIAID requires a suite of product development-oriented services to provide preclinical development support for multiple vaccine and biologic candidates. These services are intended to provide product development plans, product optimization, process development, manufacture, and characterization of candidates to support vaccine and other biologics development, acquire additional funding, gain prospective partnerships, fulfill regulatory requirements, and support Phase I/II clinical studies. https://sam.gov/opp/eec1ab7b94c7421cb11ab89a85302c91/view | Up to \$48 million, for up to 10 years | Proposal: 3/18/24 |
| | | JOINT WARFIGHTER MEDICAL (1) | | |
| 38. | Forecast: FY24 Joint Warfighter Medical Research Program (JWMP) (DoD/CDMRP) | The FY24 JWMP anticipates granting the Military Medical Research and Development Award (MMRDA) with 2 funding levels. Applicants must have already received DOD core or DOD congressionally-directed prior year funding for the same research being proposed for logical continuation under this opportunity. All proposals must address at least one of the FY24 JWMP Focus Areas . https://cdmrp.health.mil/pubs/press/2024/24jwmpreann | Up to \$3.4 million, for up to 3 years Dependent upon award mechanism | TBD |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|--|--|---|--|
| | | PATIENT-CENTERED RESEARCH (3) | | |
| 39. | Engagement Award: Stakeholder Convening Support -- April 2024 Cycle (PCORI) | The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations. https://www.pcori.org/funding-opportunities/announcement/engagement-award-stakeholder-convening-support-april-2024-cycle | Up to \$125,000, for up to 1 year | Letter of intent: 4/4/24 Invited proposals: 7/10/24 |
| 40. | Engagement Award: Dissemination Initiative -- April 2024 Cycle (PCORI) | The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making. https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-april-2024-cycle | Up to \$300,000, for up to 2 years | Letter of intent: 4/4/24 Invited proposals: 7/10/24 |
| 41. | Engagement Award: Capacity Building -- April 2024 Cycle (PCORI) | The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-april-2024-cycle | Up to \$300,000, for up to 2 years | Letter of intent: 4/4/24 Invited proposals: 7/10/24 |
| | | RADIATION EXPOSURE (1) | | |
| 42. | Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-24-003 | This NOFO supports radiation research at all stages of development for the identification of biomarkers of injury and the development of assays or devices for the purpose of triage, including assessing absorbed dose or predicting health outcomes of acute or delayed injuries resulting from radiation exposure during a public health emergency. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-003.html | Up to \$350,000 per year, for up to 5 years | Letter of intent: 4/30/24 Proposal: 5/31/24 |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|---|---|--|--|
| | | SUBSTANCE USE DISORDER (5) | | |
| 43. | <p>Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Clinical Trials vary) (NIH/NIDA)</p> <p>RFA-DA-25-032 (R01) RFA-DA-25-033 (R01) RFA-DA-25-034 (R01)</p> | <p>These NOFOs support: basic or early translational studies that may, but need not, be considered NIH clinical trials; BESH studies that consist of mechanistic, transdisciplinary research on social behavior and its relationships with the onset, trajectory, and impact of SUDs and comorbidities; and mechanistic transdisciplinary research in animal models that integrates approaches across social/cognitive neuroscience with perspectives from fields with complementary approaches to the study of social behavior.</p> <p>https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-032.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-033.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-034.html (R01)</p> | <p>Dependent upon proposal, for up to 5 years (032/033) Up to \$425,000, for up to 5 years (034)</p> | <p>Letter of intent: 7/14/24 Proposal: 8/14/24</p> |
| 44. | <p>Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42/R43/R44 Clinical Trials Not Allowed) (NIH/NIDA)</p> <p>RFA-DA-25-053 (R41/R42) RFA-DA-25-054 (R43/R44)</p> | <p>These NOFOs support research projects directed towards commercialization to harness artificial intelligence (AI), including machine learning (ML), tools, and polypharmacology to identify pharmacotherapeutics with lower toxicity and higher efficacy to prevent or treat substance use disorders (SUDs).</p> <p>https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-053.html (R41/R42) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-054.html (R43/R44)</p> | <p>Up to \$400,000, for up to 1 year (Phase I) Up to \$3 million, for up to 3 years (Phase II)</p> | <p>Letter of intent: 6/25/24 Proposal: 7/25/24</p> |
| | | THERAPEUTICS (2) | | |
| 45. | <p>Establishing Qualification Processes for Agile Pharmaceutical Manufacturing (EQUIP-A-Pharma) (DoD/DARPA)</p> <p>DARPA-PS-24-12</p> | <p>is soliciting innovative approaches to address challenges in qualifying drug products produced in an agile pharmaceutical manufacturing platform. EQUIP-A-Pharma will aim to develop the technology and process models to demonstrate real-time qualification of multiple drug products produced by reprogramming or reconfiguring the manufacturing platform and inform the creation of a future regulatory framework for agile pharmaceutical manufacturing.</p> <p>https://sam.gov/opp/d31c202c9bba464a9dccc3a7223a7ba/view</p> | <p>Up to \$500,000 for 6 months (Phase 1) Up to \$11.5 million for 1 year (Phase 2) Up to \$2 million for 6 months (Phase 3)</p> | <p>Abstracts: 2/20/24</p> |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|---|---|---|---------------------|
| | | THERAPEUTICS | | |
| 46. | Interventional Agents Chemistry Services (NIH/NIAID) 75N93024R00002 | NIAID requires a nontraditional, proactive, and product development-oriented program to provide preclinical development support for promising therapeutic candidates. The Interventional Agents Chemistry Services resource is intended for case-by-case support of diverse interventional agent product candidates rather than for carrying a single program through multiple stages of the preclinical development pathway. The provided services shall be directed at diseases caused by pathogens and toxins on the NIAID Emerging Infectious Diseases/Pathogens list (https://www.niaid.nih.gov/research/emerging-infectious-diseases-pathogens); Emerging and re-emerging infectious diseases; Antimicrobial resistant and multi-drug resistant infections; Other bacterial infections; Fungal infections; Viral infections; Parasitic diseases. https://sam.gov/opp/foo829b86fce4d259f6120bb87573300/view | Dependent upon proposal and contract | Proposal: 5/1/24 |
| | | TUBEROUS SCLEROSIS COMPLEX (3) | | |
| 47. | Forecast: FY24 Tuberos Sclerosis Complex Research Program (DoD/CDMRP) | The FY24 TSCRCP anticipates 3 awards: Exploration-Hypothesis Development Award, Idea Development Award, Clinical Translational Research Award. Applications must address one or more of the Focus Areas specific to each award. https://cdmrp.health.mil/pubs/press/2024/24tscrppreann | Up to \$1.15 million, for up to 3 years Dependent upon award mechanism | TBD |
| | | VISION HEALTH (1) | | |
| 48. | Forecast: FY24 Vision Research Program (VRP) (DoD/CDMRP) | The FY24 VRP is announcing the Mentored Clinical Research Award, with others expected to be posted after 3/15/24. Applications submitted to the FY24 VRP must address one or more of the following Focus Areas: Understanding and treatment of eye injury or visual dysfunction as related to military exposure; Diagnosis, stabilization, and treatment of eye injuries in austere environments and prolonged field care settings; Restoration of visual function after military exposure-related vision loss or severe visual impairment. https://cdmrp.health.mil/pubs/press/2024/24vrppreann | Up to \$75,000, for up to 18 months | TBD |





Recurring Opportunities

February 5, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|---|---|---|---|
| | | ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (1) | | |
| 49. | Open-Office Broad Agency Announcement (BAA) 75N99223S0001 | Awardees will develop groundbreaking new ways to tackle health-related challenges through high-potential, high-impact biomedical and health research. ARPA-H has identified four initial focus areas that are a priority for investment: (1) Health Science Futures; (2) Scalable Solutions; (3) Proactive Health; (4) Resilient Systems. https://sam.gov/opp/caf109b75a0449418ead3630cef1915e/view | Dependent upon proposal and award mechanism | Abstract: 3/14/24 |
| | | AIR FORCE (3) | | |
| 50. | Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008 | The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332 | Up to \$49 million, per award | White papers accepted on rolling basis until 5/1/25 |
| 51. | Research Interests of the Air Force Office of Scientific Research FA9550-23-S-0001 | The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). https://www.grants.gov/web/grants/view-opportunity.html?oppId=345653 | Dependent upon proposal, for up to 5 years | White papers accepted on a rolling basis |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|--|--|--|--|
| | | AIR FORCE | | |
| 52. | Research Interests of the United States Air Force Academy USAFA-BAA-2021 | USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/web/grants/view-opportunity.html?oppld=330175 | Dependent upon proposal, for up to 5 years | Proposals accepted on a rolling basis |
| | | ARMY (8) | | |
| 53. | BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01 | The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view | Dependent upon proposal | Proposals accepted on a rolling basis through 6/11/27 |
| 54. | USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1 | R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational Medicine; Medical Biological Defense; and Medical Chemical Defense. https://www.grants.gov/web/grants/view-opportunity.html?oppld=343725 | Dependent upon proposal, for up to 5 years | Pre-applications accepted until 9/30/27 Full proposal by invitation |
| 55. | USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1 | A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/web/grants/view-opportunity.html?oppld=349586 | Dependent upon proposal | Proposals accepted through 7/31/28 Submission of a pre-proposal is required |
| 56. | Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001 | ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here . https://sam.gov/opp/e68f40ea3b224b86ab14b9d5a8af7f9c/view | Dependent upon proposal | Proposals accepted on a rolling basis until 11/20/27 |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|--|--|---------------------------|---|
| | | ARMY | | |
| 57. | Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010 | ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/e8d78dcbe9e846f2af5fd1bfd04dc27c/view | Dependent upon proposal | Proposals accepted on a rolling basis until 4/30/28 Full proposal required |
| 58. | Army Applications Lab BAA for Disruptive Applications W911NF-19-S-0004 | AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct warfare. https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517 | Dependent upon proposal | Proposals accepted through 5/1/24 Pre-proposal is required |
| 59. | Army Research Office Broad Agency Announcement Staff Research Program W911NF20S0003 | The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences. https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf | Dependent upon proposal | Proposals accepted on a rolling basis until 2/19/25 |
| 60. | Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022 | Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285 | Dependent upon proposal | Proposals accepted on a rolling basis until 2/28/25 |
| | | BARDA (2) | | |
| 61. | BARDA Broad Agency Announcement BAA-23-100-SOL-00004 | BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/645772ab7baf41d7aa0a6cbbec012147/view | Dependent upon proposal | Proposal: 9/25/28 |
| 62. | BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003 | BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #15: ReDIRECT; AOI #16: Lab at Home; AOI #19: Healing Lungs; AOI #20: DRIVE Forward; AOI #25: FASTx; AOI #27: Stopping Secondary Spread. https://sam.gov/opp/79482f9236c64929938197ae21e9347a/view | Up to \$750,000 per award | Proposals accepted on a rolling basis Deadlines vary by AOI |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|---|---|---|---|
| | | DARPA (2) | | |
| 63. | Biological Technologies BAA HR001123S0045 | Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/597bf60984314db1b3ecfce393677c75/view | Dependent upon proposal | Abstracts & proposals accepted on a rolling basis until 6/20/24 |
| 64. | Defense Sciences Office, Office-wide HR001123S0053 | The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats. https://sam.gov/opp/972be70efd7e4608b01311466edf6bof/view | Dependent upon proposal | Abstracts accepted on a rolling basis until 9/26/24 |
| | | DEFENSE THREAT REDUCTION AGENCY (2) | | |
| 65. | Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-14-24-FRCWMD-BAA | DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view | Up to \$1 million per year, for up to 5 years | White papers accepted through 9/2024 |
| 66. | Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003 | DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): <ul style="list-style-type: none"> • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/e23f86536f7840eaa868f3526a86a6ae/view | Dependent upon proposal, for up to 18 months | White papers accepted on a rolling basis through 2/14/27 |
| | | DEPARTMENT OF ENERGY (1) | | |
| 67. | FY 2024 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003177 | By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/web/grants/view-opportunity.html?oppId=350408 | Dependent upon award mechanism | Proposals accepted on a rolling basis through 9/30/24 |



| | Title (Agency) and Opportunity # | Description and Link | Funding Level | Deadline |
|-----|---|---|---|--|
| | | NATIONAL SCIENCE FOUNDATION (1) | | |
| 68. | Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 23-515 | The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. View the full list of topics here . https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm | Up to \$275,000 for up to 1 year | Project pitches accepted on a rolling basis. Submission window for invited proposals: 7/6/23 to 3/4/24 |
| | | NAVY (3) | | |
| 69. | FY23 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943023S2501 | This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/14178e9157ad40b387ddb443071b0969/view | Dependent upon proposal | Abstracts accepted on a rolling basis until 4/11/24 |
| 70. | Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001424SB001 | The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.nre.navy.mil/work-with-us/funding-opportunities/fy24-long-range-broad-agency-announcement-baa-navy-and-marine | Dependent upon proposal | Proposals accepted on a rolling basis until 9/30/24 |
| 71. | NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-23-S-BA01 | The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/ee708f6d2e244dobb59d582co362d9d1/view | Dependent upon proposal and award mechanism | White papers accepted through 3/29/24 |





Terms

AD/ADRD: Alzheimer's Disease / Alzheimer's Disease Related Dementias

Aoi: Area of Interest

BAA: Broad Agency Announcement

BBB: Blood-Brain Barrier

CNS: Central Nervous System

FOA: Funding Opportunity Announcement

IC: NIH Institutes and Centers

NOFO: Notice of Funding Opportunity

NOSI: Notice of Special Interest

PI: Principal Investigator

PTSD: Post-Traumatic Stress Disorder

RFI: Request for Information

RFP: Request for Proposal

SBIR: Small Business Innovation Research

SDOH: Social Determinants of Health

STTR: Small Business Technology Transfer

SUD: Substance Use Disorder

TRL: Technology Readiness Level

VCID: Vascular Contributions to Cognitive Impairment and Dementia

Agencies

ARPA-H: Advanced Research Projects Agency for Health

ASPR: Administration for Strategic Preparedness and Response

BARDA: Biomedical Advanced Research and Development Authority

CDC: Centers for Disease Control and Prevention

CDMRP: Congressionally Directed Medical Research Programs

DARPA: Defense Advanced Research Projects Agency

DHA: Defense Health Agency

DoD: Department of Defense

FDA: U.S. Food and Drug Administration

MTEC: Medical Technology Enterprise Consortium

NIH: National Institutes of Health

[Back to Table of Contents](#)

GBG Acronyms

Updated Monthly

February 5, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

NSF: National Science Foundation

PCORI: Patient-Centered Outcomes Research Institute

USAMRDC: U.S. Army Medical Research and Development Command

USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases

USSOCOM: United States Special Operations Command

NIH Institutes and Centers

CC: NIH Clinical Center

CIT: NIH Center for Information Technology

CSR: NIH Center for Scientific Review

FIC: Fogarty International Center

NCATS: National Center for Advancing Translational Sciences

NCCIH: National Center for Complementary and Integrative Health

NCI: National Cancer Institute

NEI: National Eye Institute

NHGRI: National Human Genome Research Institute

NHLBI: National Heart, Lung, and Blood Institute

NIA: National Institute on Aging

NIAAA: National Institute on Alcohol Abuse and Alcoholism

NIAID: National Institute of Allergy and Infectious Diseases

NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases

NIBIB: National Institute of Biomedical Imaging and Bioengineering

NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development

NIDA: National Institute on Drug Abuse

NIDCD: National Institute on Deafness and Other Communication Disorders

NIDCR: National Institute of Dental and Craniofacial Research

NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases

NIEHS: National Institute of Environmental Health Sciences

NIGMS: National Institute of General Medical Sciences

NIMH: National Institute of Mental Health

NIMHD: National Institute on Minority Health and Health Disparities

NINDS: National Institute of Neurological Disorders and Stroke

NINR: National Institute of Nursing Research

NLM: National Library of Medicine

